StreetTalk: Enter the Dragon: China Biopharm Market is a Land of Opportunity for Investors - US companies who have yet to establish a presence in China run the risk of being left behind - BioPharm

ADVERTISEMENT

StreetTalk: Enter the Dragon: China Biopharm Market is a Land of Opportunity for Investors
US companies who have yet to establish a presence in China run the risk of being left behind


BioPharm International
Volume 19, Issue 6

Fair play? Maybe not. But eminently possible in a country that takes so many of its health care cues from the West. Another door opens for US drug makers because the vast majority of life sciences companies in China are marketing traditional Chinese medicine, where quality issues comes into play. With so many American-educated Chinese doctors and medical researchers heading back home to ply their craft in China, chances are many will be taking their US training back home with them—at the expense of Chinese medicine and drugs. These doctorate-carrying expatriates will convince their countrymen and women that Nexium is probably a better bet for stomach problems than bear bile or gum tree extract.

Another issue that is potentially beneficial to US biopharm companies is the fact that 90% of Chinese in major cities like Shanghai, Beijing, and Guangzhou are covered by state-sponsored health plans. That's a ready made customer base that's at least 80 million strong, leaving plenty of opportunities for US companies to make their case to Chinese consumers, if they can get past the preference (for now) of cheaper generic drugs by thrifty government health care officials.

CAUSE FOR CONCERN

One issue that has haunted US drug companies looking to operate in China is the propensity of Chinese biopharm companies to rely on counterfeit drugs. But in July 2005, the US and China agreed on a long-awaited reform on patent protections that should inoculate US companies from Chinese counterfeiters. Now, Chinese companies that engage in patent infringement and counterfeiting could face fines and penalties of anywhere between $400 million and $1 billion.

Outside of the intellectual property issue, US biopharm companies can't expect too much more help from Chinese authorities, especially in terms of seed money for new life sciences ventures.

While the Chinese government does spend about $600 million annually on biotech research and development, further sources of local funding are few and far between. In recent years, China has opened a funding pipeline through local venture capital firms but money is scarce and typical investments rarely reach the $1 million or $2 million that new biopharm ventures can count on in Western countries. Still, labor costs are low in China and the government can contribute in other ways, especially in added funding for infrastructure and other industrial needs that foreign companies need when setting up shop in China.

US companies who have yet to establish a presence in China run the risk of being left behind. Already, firms from other Western countries like Canada (Dragon Pharmaceuticals) and the United Kingdom (GeneMedix PLC) have established successful manufacturing bases in China.

Some companies are looking to play catch-up via the acquisition route. That's what US-based Invitrogen Corporation did through its purchase of BioAsia, a Shanghai-based bio-services company.

Invitrogen, like the handful of US companies that preceded it into China, all see the same profitable landscape. Low-cost levels of entry, a low-cost, yet highly-skilled labor pool, a government bound and determined to establish a haven for life sciences companies, and a vast consumer market of Chinese looking to step forward into the healing light of 21st century healthcare.

"Add in China's entrepreneurial culture and it all indicates a promising future," notes Matthew Chervenak, president and founder of General Biologic, a Shanghai-based professional services firm. "If China implements appropriate regulatory structures for IP protection and capital markets, which may take a long time, the industry's natural drivers will make China's emergence as a strong player in the field inevitable. Within many products and services sectors, China is poised for dominance."

Celebrity author and business/finance commentator for CNN and Fox News, Brian O'Connell has written for The Wall Street Journal and Newsweek, 79 Radcliffe Drive, Doylestown, PA 18901, 267.880.3144, fax 267.880.1939,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Author Guidelines
Source: BioPharm International,
Click here